Clinical Trials: Page 2
-
Adam Berry via Getty Images
CT scans offer new path to diagnose treatable cause of high blood pressure, study shows
While the approach could increase demand for CT imaging, the supply of radioactive tracers is potentially a barrier to adoption of the technique.
By Nick Paul Taylor • Jan. 19, 2023 -
yodiyim via Getty Images
AI predicts lung cancer risk six years into the future using single CT scan: study
A research team has made the deep learning model publicly available and says it has no intention to commercialize it.
By Nick Paul Taylor • Jan. 17, 2023 -
Courtesy of LabCorp
Labcorp hires ex-Quintiles CEO to lead clinical development unit ahead of upcoming spinoff
Thomas Pike, who oversaw the transformational merger of Quintiles and IMS Health, will be in charge of a CRO for the first time since 2016.
By Nick Paul Taylor • Jan. 6, 2023 -
Lisa Maree Williams via Getty Images
AstraZeneca extends C2i pact to validate minimal residual disease solid tumor blood test
The technology could improve cancer treatment and support clinical trial recruitment and monitoring.
By Nick Paul Taylor • Jan. 6, 2023 -
SciePro via Getty Images
Novocure shares jump on positive lung cancer data
A regimen involving the Swiss biotech’s electrical field-based treatment extended lives in a late-stage trial. But data comparing the medical device to standard chemotherapy is less persuasive.
By Jonathan Gardner • Jan. 5, 2023 -
Permission granted by Freenome
Q&AFreenome CEO Mike Nolan talks colorectal cancer test, clinical trials
The San Francisco-based company recently enrolled a clinical trial for its blood-based cancer test but faces competition in the market for minimally invasive cancer tests.
By Elise Reuter • Dec. 22, 2022 -
Courtesy of Medtronic
Medtronic starts US robotic surgery trial in push to challenge Intuitive
Medtronic delayed the Hugo program to make changes in light of surgeon feedback, but now plans to evaluate the use of the surgical robot in urologic procedures, facing off against competitor Intuitive.
By Nick Paul Taylor • Dec. 20, 2022 -
titoOnz via Getty Images
MDR costs are driving manufacturers to pull products from European market: report
The report adds to evidence that makers of products used for pediatric patients and rare diseases have been particularly hard hit.
By Nick Paul Taylor • Dec. 20, 2022 -
Guardant Health
Pivotal data on Guardant’s colorectal cancer blood test raise doubts about commercial prospects
Guardant’s share price fell 27% after the release of the news, which raised questions about whether the test can drive sales growth.
By Nick Paul Taylor • Dec. 19, 2022 -
Courtesy of Synchron
Gates, Bezos invest in Synchron’s brain computer interface
A $75 million investment will accelerate the development of a drill-free implant to help patients with upper-limb paralysis.
By Peter Green • Dec. 16, 2022 -
Courtesy of Vaxxas
Investors hand Vaxxas $23M to support trial of needle-free COVID-19 vaccine
With support from the Gates Foundation, the needle-free technology could get more people vaccinated and avoid cold-chain issues.
By Nick Paul Taylor • Dec. 12, 2022 -
Johnny Greig via Getty Images
The 10 biggest medtech stories of 2022
MedTech Dive reporting this year has explored how companies maintained momentum even amid supply shortages and rising inflation rates.
By MedTech Dive staff • Dec. 3, 2022 -
Courtesy of UroMems
UroMems starts clinical trial of smart, automated implant to treat incontinence
The device is designed to improve on products such as Boston Scientific’s AMS 800 by eliminating the need for manual adjustments.
By Nick Paul Taylor • Nov. 30, 2022 -
Courtesy of Apple
Apple earbuds show promise as hearing aids in clinical trial
The earbuds performed comparably to hearing aids in terms of speech perception in quiet environments.
By Nick Paul Taylor • Nov. 22, 2022 -
Permission granted by Medtronic
Medtronic’s renal denervation treatment ‘still a viable therapy’ despite study miss, doctors say
While the study missed its primary endpoint, the surgery likely will be an option for patients with drug-resistant hypertension.
By Elise Reuter • Nov. 17, 2022 -
Courtesy of Tandem Diabetes
Tandem pump, paired with Dexcom CGM, boosts blood glucose control in Type 2 diabetics
Patients with Type 2 diabetes spent 3.6 hours per day longer in the target blood glucose range after switching to Tandem’s system, a study found.
By Nick Paul Taylor • Nov. 14, 2022 -
Wavebreakmedia via Getty Images
Green light shows promise in addressing oximetry racial bias: study
Researchers created a noninvasive device that performed comparably to Abbott’s invasive i-STAT in a small clinical trial.
By Nick Paul Taylor • Nov. 14, 2022 -
Courtesy of Dr. Nada Ali/University of Washington
Affordable alternative: Smartphone-based hearing test for infants targets developing countries
The off-the-shelf alternative has a material cost of $10, giving children in impoverished regions easier access to vital monitoring and diagnosis.
By Nick Paul Taylor • Nov. 9, 2022 -
Medtronic
Medtronic misses primary endpoint in renal denervation study
The device didn't outperform drug therapy when patients measured their blood pressure at home, though it's still expected to win FDA approval.
By Elise Reuter • Nov. 8, 2022 -
Courtesy of Medtronic
Medtronic’s AFib ablation device beats antiarrhythmic drugs in 3-year study
Arctic Front cryoablation devices show promise as an early treatment for atrial fibrillation.
By Nick Paul Taylor • Nov. 8, 2022 -
Courtesy of Abiomed
Abiomed wraps up Impella post-approval studies requested by FDA
Abiomed’s studies linked the device to a 22% to 45% improvement in the volume of blood pumped after 90 days, suggesting it’s a viable alternative to balloon therapy.
By Nick Paul Taylor • Oct. 21, 2022 -
bymuratdeniz via Getty Images
AI matches humans at detecting mental health red flags in text messages, study shows
The study suggests algorithms have the potential to enable automated tools for clinical support of people with mental illness.
By Nick Paul Taylor • Oct. 13, 2022 -
‘Do-it-yourself’ artificial pancreas system beats production-line pump in controlled trial
Type 1 diabetes patients who used a customizable, open-source artificial pancreas, an insulin pump and a Dexcom G6 CGM found it more effective at controlling blood glucose than conventional sensor-augmented insulin pumps.
By Nick Paul Taylor • Oct. 12, 2022 -
Sarah Silbiger via Getty Images
FDA finalizes postapproval study guidance in light of AdvaMed, Foundation Medicine feedback
The agency resisted calls to give sponsors more time to prepare protocols for post-approval studies.
By Nick Paul Taylor • Oct. 11, 2022 -
Retrieved from Abbott/PRNewswire on June 15, 2020
Abbott’s FreeStyle Libre 2 CGM beats fingerstick testing in independent clinical trial
Going into the study, the researchers were unsure if CGMs with optional alarms for high and low blood glucose levels benefit patients with Type 1 diabetes.
By Nick Paul Taylor • Oct. 11, 2022
Previous
